JP2017524013A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524013A5
JP2017524013A5 JP2017507775A JP2017507775A JP2017524013A5 JP 2017524013 A5 JP2017524013 A5 JP 2017524013A5 JP 2017507775 A JP2017507775 A JP 2017507775A JP 2017507775 A JP2017507775 A JP 2017507775A JP 2017524013 A5 JP2017524013 A5 JP 2017524013A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
hydrogen
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017507775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524013A (ja
JP6250226B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/068349 external-priority patent/WO2016023858A1/en
Publication of JP2017524013A publication Critical patent/JP2017524013A/ja
Publication of JP2017524013A5 publication Critical patent/JP2017524013A5/ja
Application granted granted Critical
Publication of JP6250226B2 publication Critical patent/JP6250226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017507775A 2014-08-11 2015-08-10 Smac模倣薬としての6−アルキニル−ピリジン誘導体 Active JP6250226B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14180554.9 2014-08-11
EP14180554 2014-08-11
PCT/EP2015/068349 WO2016023858A1 (en) 2014-08-11 2015-08-10 6-alkynyl-pyridine derivatives as smac mimetics

Publications (3)

Publication Number Publication Date
JP2017524013A JP2017524013A (ja) 2017-08-24
JP2017524013A5 true JP2017524013A5 (https=) 2017-10-05
JP6250226B2 JP6250226B2 (ja) 2017-12-20

Family

ID=51300621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507775A Active JP6250226B2 (ja) 2014-08-11 2015-08-10 Smac模倣薬としての6−アルキニル−ピリジン誘導体

Country Status (34)

Country Link
US (4) US9481673B2 (https=)
EP (1) EP3180339B1 (https=)
JP (1) JP6250226B2 (https=)
KR (1) KR102445744B1 (https=)
CN (2) CN106573930B (https=)
AP (1) AP2017009718A0 (https=)
AR (1) AR101479A1 (https=)
AU (1) AU2015303308B2 (https=)
BR (1) BR112017002498B1 (https=)
CA (1) CA2956123C (https=)
CL (1) CL2017000326A1 (https=)
CO (1) CO2017001226A2 (https=)
CY (1) CY1121273T1 (https=)
DK (1) DK3180339T3 (https=)
EA (1) EA031424B1 (https=)
ES (1) ES2711763T3 (https=)
HR (1) HRP20190336T1 (https=)
HU (1) HUE043915T2 (https=)
IL (1) IL249844B (https=)
LT (1) LT3180339T (https=)
ME (1) ME03303B (https=)
MX (1) MX2017001835A (https=)
NZ (1) NZ728073A (https=)
PE (1) PE20170193A1 (https=)
PH (1) PH12017500231A1 (https=)
PL (1) PL3180339T3 (https=)
PT (1) PT3180339T (https=)
RS (1) RS58355B1 (https=)
SG (1) SG11201700999YA (https=)
SI (1) SI3180339T1 (https=)
TR (1) TR201902023T4 (https=)
TW (1) TWI723959B (https=)
UA (1) UA118887C2 (https=)
WO (1) WO2016023858A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
KR102392581B1 (ko) * 2016-05-19 2022-04-28 베링거 인겔하임 인터내셔날 게엠베하 6-알키닐-피리딘 유도체의 제조 방법
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018178250A1 (en) 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
TWI894135B (zh) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
PH12022550721A1 (en) 2019-09-25 2024-05-13 Debiopharm Int Sa Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
CR20220606A (es) 2020-06-03 2023-01-23 Boehringer Ingelheim Int Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234360A1 (en) 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
US7989441B2 (en) 2005-06-08 2011-08-02 Novartis Ag Organic compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0720049A2 (pt) * 2006-12-07 2014-01-07 Novartis Ag Derivados de piridina utilizados como inibidores de xiap
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
AR101479A1 (es) 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina

Similar Documents

Publication Publication Date Title
JP2017524013A5 (https=)
JP2015508103A5 (https=)
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
JP2017525730A5 (https=)
JP2019524883A5 (https=)
JP2016530259A5 (https=)
JP2019517487A5 (https=)
JP2015501833A5 (https=)
JP2013522292A5 (https=)
JP2016522266A5 (https=)
JP2018516917A5 (https=)
JP2016040288A5 (https=)
JP2015514806A5 (https=)
JP2018525441A5 (https=)
JP2012153722A5 (https=)
RU2015118135A (ru) Содержащие заместители бензольные соединения
JP2016503799A5 (https=)
JP2015512943A5 (https=)
JP2019528307A5 (https=)
JP2013502441A5 (https=)
JP2017501237A5 (https=)
HRP20192101T1 (hr) Inhibitori ezh2
JP2016531126A5 (https=)
JP2019500315A5 (https=)
JP2014510147A5 (https=)